Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  American Journal of Cardiology

• Publication date

  1988-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0002-9149(88)90553-XPMID 3189171
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy.

  1988cited by this paper
• Hypertrophic cardiomyopathy.

  1987cited by this paper
• Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2).

  1987cited by this paper
• Hypertrophic cardiomyopathy: a 1987 viewpoint.

  1987cited by this paper
• Disopyramide‐Pyridostigmine: Report of a Beneficial Drug Interaction

  1985cited by this paper
• Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review.

  1985cited by this paper
• Doppler ultrasound in cardiology

  1985cited by this paper
• Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient.

  1984cited by this paper
• Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide.

  1982cited by this paper
• The Cardiac Effects of d‐ and 1‐Disopyramide in Normal Subjects: A Noninvasive Study

  1982cited by this paper
• Drug therapy: bretylium.

  1979cited by this paper
• Disopyramide.

  1979cited by this paper

• Treatment patterns, outcomes and healthcare resource utilization of obstructive hypertrophic cardiomyopathy in England

  2025cites this paper
• Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy.

  2025cites this paper
• Disopyramide for symptomatic obstructive hypertrophic cardiomyopathy.

  2025cites this paper
• Efficacy of pharmacological therapies in reducing outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis

  2025cites this paper
• Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy

  2025cites this paper
• Diretriz sobre Diagnóstico e Tratamento da Cardiomiopatia Hipertrófica – 2024

  2024cites this paper
• Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024

  2024cites this paper
• Medical Therapies to Improve Left Ventricular Outflow Obstruction and Diastolic Function in Hypertrophic Cardiomyopathy

  2023cites this paper
• Obstructive hypertrophic cardiomyopathy: a review of new therapies.

  2023cites this paper
• Multi-modality management of hypertrophic cardiomyopathy

  2023cites this paper
• Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside

  2022cites this paper
• Efficacy of cibenzoline for hypertrophic obstructive cardiomyopathy in paediatric patients with RAS/MAPK pathway syndromes.

  2022cites this paper
• Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy.

  2020cites this paper
• Out With the Old and in With the New

  2019cites this paper
• Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy.

  2019cites this paper
• Anti‐arrhythmic therapy in patients with non‐ischemic cardiomyopathy

  2019cites this paper
• Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy

  2019cites this paper
• Pharmacological and non-pharmacological treatment of obstructive hypertrophic cardiomyopathy

  2018cites this paper
• Medical Therapy: From Beta-Blockers to Disopyramide

  2018cites this paper
• Cardiovascular Genetics and Genomics

  2018cites this paper
• Inherited Cardiac Muscle Disorders: Hypertrophic and Restrictive Cardiomyopathies

  2018cites this paper
• Drug Therapy in Adult Congenital Heart Disease.

  2017cites this paper
• Miocardiopatías en la infancia

  2016cites this paper
• Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice

  2016cites this paper
• Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug

  2015cites this paper
• Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide

  2015cites this paper
• Medical Therapy: From Beta–Blockers to Disopyramide

  2015cites this paper
• Advances in medical treatment of hypertrophic cardiomyopathy.

  2014cites this paper
• 11. Hypertrophic Cardiomyopathy

  2013cites this paper
• Cardiomyopathie hypertrophique : aspects actuels et nouveautés

  2012cites this paper
• [Hypertrophic cardiomyopathy: current aspects and new developments].

  2012cites this paper
• A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.

  2012cites this paper
• Treatment of hypertrophic cardiomyopathy in childhood

  2011cites this paper
• 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2011cites this paper
• 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2011cites this paper
• 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci

  2011cites this paper
• 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cites this paper
• 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cites this paper
• Hypertrophic Cardiomyopathy in a Young Adult with RV Aneurysm: Report of a Rare Finding and Review of the Literature

  2011cites this paper
• AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy : Executive summary

  2011cites this paper
• Hypertrophic cardiomyopathy.

  2011cites this paper
• Foundation/American Heart Association Task Force on Practice Guidelines Cardiomyopathy : A Report of the American College of Cardiology 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic

  2011cites this paper
• Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy.

  2010cites this paper
• Possible acute and chronic synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy: a case report

  2010cites this paper
• Surgery for Congenital Anomalies of the Aortic Valve and Root

  2010cites this paper
• Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.

  2010cites this paper
• Pulmonary Vein Isolation using a High Density Mesh Ablator Catheter: Incorporation of three-Dimensional Navigation and Mappin.

  2009cites this paper
• Atrial Fibrillation in Hypertrophic Obstructive Cardiomyopathy - Antiarrhythmics, Ablation and More!

  2009cites this paper
• Alcohol septal ablation in hypertrophic obstructive cardiomyopathy.

  2009cites this paper
• Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.

  2008cites this paper
• Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy: its relationship to transmitral Doppler flow profiles.

  2007cites this paper
• Electrochemical Oxidation at a Glassy Carbon Electrode of the Anti‐Arrhythmia Drug Disopyramide

  2007cites this paper
• Practice Guidelines Consensus Documents and the European Society of Cardiology Committee for

  2007cites this paper
• Hypertrophic Cardiomyopathy Update on Prognosis and Therapy

  2006cites this paper
• Pathophysiology and treatment of hypertrophic cardiomyopathy.

  2006cites this paper
• Insuffisance cardiaque du nourrisson et du nouveau-né

  2006cites this paper
• Selection of hypertrophic cardiomyopathy patients for myectomy or alcohol septal ablation.

  2006cites this paper
• A case report

  2006cites this paper
• Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.

  2005cites this paper
• Multicenter Study of the Efficacy and Safety of Disopyramide in Obstructive Hypertrophic Cardiomyopathy

  2005cites this paper
• Hypertrophic cardiomyopathy in Northern Sweden : with special emphasis on molecular genetics

  2004cites this paper
• Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing

  2004cites this paper
• Hypertrophic cardiomyopathy in childhood.

  2004cites this paper
• Hypertrophic cardiomyopathy.

  2004cites this paper
• Hypertrophic cardiomyopathy

  2004cites this paper
• Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction.

  2003cites this paper
• Expert consensus document American College of Cardiology / European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy

  2003cites this paper
• American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G

  2003cites this paper
• Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy.

  2003cites this paper
• American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G

  2003cites this paper
• A new algorithm for rhythm discrimination in cardioverter defibrillators based on the initial voltage changes of the ventricular electrogram.

  2003cites this paper
• Maron Hypertrophic Cardiomyopathy : A Systematic Review

  2002cites this paper
• Insuffisance cardiaque du nourrisson et du nouveau-né

  2002cites this paper
• NONSURGICAL REDUCTION OF THE INTERVENTRICULAR SEPTUM IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY

  2002cites this paper
• Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy.

  2002cites this paper
• Hypertrophic cardiomyopathy: a systematic review.

  2002cites this paper
• Effect of Cibenzoline, a Class Ia Antiarrhythmic Agent, on Left Ventricular Diastolic Function in Hypertrophic Cardiomyopathy

  2001cites this paper
• Exercise-induced neurocardiogenic syncope: clinical data, pathophysiological aspects, and potential role of tilt table testing.

  2000cites this paper
• Percutaneous transluminal septal myocardial ablation

  2000cites this paper
• Pacemaker Treatment for Hypertrophic Obstructive Cardiomyopathy: Are Long-Term Results as Good as Short-Term Ones?

  2000cites this paper
• Medical treatment of hypertrophic cardiomyopathy

  2000cites this paper
• Outcome of Septal Myectomy in Patients with Hypertrophic Obstructive Cardiomyopathy

  2000cites this paper
• Effect of cibenzoline on regional left ventricular function in hypertrophic obstructive cardiomyopathy

  2000cites this paper
• Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC) Study Group.

  1999cites this paper
• Effect of Disopyramide on Left Ventricular Pressure Gradient in Hypertrophic Obstructive Cardiomyopathy in Comparison with Propranolol

  1999cites this paper
• Pediatric myocardial disease.

  1999cites this paper
• Schrittmachertherapie bei hypertroph-obstruktiver Kardiomyopathie

  1999cites this paper
• 症例 ジソピラミドにより心室内圧較差が著明に減少し,症状が好転した家族性肥大型心筋症の1例

  1999cites this paper
• Cardiomyopathie hypertrophique

  1999cites this paper
• Transluminal percutaneous septal myocardial ablation in a patient with hypertrophic obstructive cardiomyopathy.

  1998cites this paper
• Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy.

  1998cites this paper
• Cardiomiopatia hipertrófica tratada por técnica intervencionista de redução septal

  1998cites this paper
• Spontaneous Variability of Left Ventricular Outflow Tract Gradient in Hypertrophic Obstructive Cardiomyopathy

  1998cites this paper
• Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy.

  1997cites this paper
• Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients.

  1997cites this paper
• Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group.

  1997cites this paper
• Non-surgical septum reduction in hypertrophic cardiomyopathy

  1996cites this paper
• Which Therapeutic Approach for Patients with Hypertrophic Cardiomyopathy and Ventricular Arrhythmias

  1996cites this paper
• The Treatment of Hypertrophic Obstructive Cardiomyopathy by Nonsurgical Myocardial Reduction

  1996cites this paper
• Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failure.

  1996cites this paper